Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 6.48B | 6.48B | 5.56B | 5.91B | 5.99B | 5.48B |
Gross Profit | 1.75B | 1.66B | 2.25B | 2.18B | 2.00B | 1.96B |
EBITDA | 820.40M | 944.10M | 605.10M | 711.80M | 625.77M | 545.57M |
Net Income | 348.50M | 453.20M | 265.70M | 284.91M | 407.24M | 617.65M |
Balance Sheet | ||||||
Total Assets | 0.00 | 7.16B | 6.01B | 6.27B | 5.80B | 5.56B |
Cash, Cash Equivalents and Short-Term Investments | 1.34B | 1.64B | 749.20M | 838.05M | 453.11M | 288.79M |
Total Debt | 0.00 | 16.90M | 422.90M | 413.25M | 428.45M | 513.18M |
Total Liabilities | -4.94B | 1.55B | 1.41B | 1.39B | 1.39B | 1.56B |
Stockholders Equity | 4.94B | 5.61B | 4.60B | 4.88B | 4.40B | 4.00B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 812.90M | 288.02M | 278.40M | 272.94M | 1.25B |
Operating Cash Flow | 0.00 | 909.20M | 366.20M | 372.85M | 410.01M | 1.33B |
Investing Cash Flow | 0.00 | -807.90M | -508.30M | -72.09M | -166.26M | 557.16M |
Financing Cash Flow | 0.00 | -9.50M | -5.70M | -10.83M | -94.77M | -1.62B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | ₹6.18B | 11.48 | ― | 9.15% | 88.32% | ||
62 Neutral | ₹6.16B | 2.97 | ― | -68.96% | -30.30% | ||
57 Neutral | ₹6.32B | 21.21 | ― | 37.51% | 122.56% | ||
54 Neutral | ₹4.71B | 47.02 | 0.29% | -9.90% | 33.18% | ||
54 Neutral | ₹3.65B | 38.50 | ― | -3.36% | -47.58% | ||
51 Neutral | $7.95B | -0.40 | -41.67% | 2.21% | 22.29% | -1.85% | |
43 Neutral | ₹3.29B | 30.02 | ― | -3.41% | -3028.44% |
Venus Remedies Limited has announced a newspaper publication regarding its Annual General Meeting (AGM) notice. This announcement is part of the company’s regulatory compliance under Regulation 30 of the Listing Obligations and Disclosure Requirements (LODR). The publication ensures that stakeholders are informed about the AGM, which is a critical event for discussing the company’s performance and future strategies.